Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Triple therapy shows promise for tough-to-treat bile duct cancer

NCT ID NCT06178445

First seen Apr 17, 2026 · Last updated Apr 29, 2026 · Updated 4 times

Summary

This study tests a three-drug combination (chemotherapy plus two targeted drugs) as a first treatment for people with advanced HER2-positive bile duct or gallbladder cancer that cannot be removed by surgery. The goal is to see how well the drugs shrink tumors and control the disease. About 24 adults will take part in this early-phase trial.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BILIARY TRACT CANCER are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • Charité Universitätsmedizin

    Berlin, Germany

  • Hämatologisch-Onkologische Praxis Eppendorf (HOPE)

    Hamburg, Germany

  • Krankenhaus Nordwest (KHNW)

    Frankfurt, Germany

  • LMU München

    München, Germany

  • Medizinische Hochschule Hannover

    Hanover, Germany

  • Universitätsklinikum Augsburg

    Augsburg, Germany

  • Universitätsklinikum Freiburg

    Freiburg im Breisgau, Germany

  • Universitätsklinikum Göttingen

    Göttingen, Germany

Conditions

Explore the condition pages connected to this study.